Immunocore Holdings plc (IMCR)
NASDAQ: IMCR · Real-Time Price · USD
32.76
-0.24 (-0.73%)
Aug 14, 2025, 11:31 AM - Market open
Immunocore Holdings Revenue
Immunocore Holdings had revenue of $97.96M in the quarter ending June 30, 2025, with 29.93% growth. This brings the company's revenue in the last twelve months to $356.15M, up 26.78% year-over-year. In the year 2024, Immunocore Holdings had annual revenue of $310.20M with 24.37% growth.
Revenue (ttm)
$356.15M
Revenue Growth
+26.78%
P/S Ratio
4.64
Revenue / Employee
$722,404
Employees
493
Market Cap
1.65B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 310.20M | 60.77M | 24.37% |
Dec 31, 2023 | 249.43M | 75.07M | 43.05% |
Dec 31, 2022 | 174.36M | 137.88M | 377.91% |
Dec 31, 2021 | 36.48M | -4.63M | -11.26% |
Dec 31, 2020 | 41.11M | 7.12M | 20.94% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
IMCR News
- 5 days ago - Immunocore Holdings plc (IMCR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Immunocore reports second quarter financial results and provides a business update - GlobeNewsWire
- 14 days ago - Immunocore to report second quarter 2025 financial results and host call on August 7, 2025 - GlobeNewsWire
- 6 weeks ago - Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions - GlobeNewsWire
- 2 months ago - Immunocore to present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Immunocore reports first quarter financial results and provides a business update - GlobeNewsWire
- 4 months ago - Immunocore to present at upcoming investor conferences - GlobeNewsWire
- 5 months ago - Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - GlobeNewsWire